B+
Bull case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-09-13 · RankAlpha Sentiment Codex
SNDX
SyndaxANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-13
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Available coverage is limited but favorable toward Q2 revenue growth and commercial execution. The evidence supports cautious optimism rather than a high-conviction rerating: market-reaction attribution and post-earnings analyst revisions are unavailable, while social, options, short-interest, and employee-sentiment inputs lack sufficient coverage and should not be interpreted as neutral or positive signals.
RankAlpha Sentiment Codex - 2026-09-13
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-15catalystRevuforj commercial uptake and treatment durationHigh impact
Revuforj generated $54.7 million of Q2 2026 net revenue, up 91% year over year and 12% sequentially, while prescriptions increased 15% sequentially. Management attributed growth partly to longer treatment duration, but noted fluctuations in new-patient starts; the next commercial update should test whether duration-led growth persists [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-12].
2026-12-31eventAxatilimab Phase 2 topline readoutsHigh impact
Syndax expects Q4 2026 topline data from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis and frontline chronic graft-versus-host disease. Favorable results could materially expand the program's opportunity, while disappointing data would impair pipeline optionality [#SEC-8K-2026-08-04].
2027-09-30catalystRevuforj frontline AML expansionHigh impact
Management reported global site initiation and patient enrollment in pivotal frontline AML trials. Successful development could broaden Revuforj beyond its current settings, but timing and clinical outcomes remain uncertain [#SEC-8K-2026-08-04].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-13 • Updated nightlySource: Internal modelMethodology